A-B

· Backman, J.T., Olkkola, K.T. & Neuvonen, P.J. Rifampin drastically reduces plasma concentrations and effects of oral midazolam. Clin. Pharmacol. Ther. 1996 ; 59 : 7-13.

· Ballenger, J.C. Long-term pharmacologic treatment of panic disorder. J. Clin. Psychiatry. 1991; 52:18-23.

· Ballenger, J.C. et al. Alprazolam in panic disorder and agoraphobia: results from a multicenter trial, I: efficacy in short-term treatment. Arch. Gen. Psychiatry. 1988; 455:413-422.

· Ballenger, J.C. Benzodiazepines. In Schatzberg, A. & Nemeroff, C.B. (eds.) Textbook of psychopharmacology. American Psychiatric Press. Washington, 1995.

· Baughman, O.L. The safety record of buspirone in gneralized anxiety disorder (monograph). J. Clin. Psychiatry. 1994; 12:37-45.

· Bertilsson, L., Henthorn, T.K., Sanz, E. et al. Importance of genetic factors in the regulation of diazepam metabolism : relationship to S-mephenytoin, but not debrisoquine hydroxylation phenotype. Clin. Pharmacol. Ther. 1989 ; 45 : 348-355.

Principio de página

C

· Charney, D.S. & Woods, S.W. Benzodiazepine treatment of panic disorder: a comparison of alprazolam and lorazepam. J. Clin. Psychiatry. 1989; 50:418-423.

· Chouinard, G. et al. Alprazolam in the treatment of generalized anxiety and panic disorders. Psychopharmacology. 1982; 77.

· Chouinard, G., Young, S.N. & Annable, L. Antimaniac effects of clonazepam. Biol. Psychiatry. 1983; 18:451-466.

· Ciraulo, D.A., Barnhill, J.G., Ciraulo, A.M. et al. Parental alcoholism as a risk factor in benzodiazepine abuse : a pilot study. Am. J. Psychiatry. 1989 ; 146 : 1333-1335.

· Ciraulo, D.A. & Shader, R.I. Buspirone and MAOI therapy (letter). J. Clin. Psychopharmacol. 1990a ; 10 : 306.

· Cole, J.O., Orzack, M.H., Beake, B. et al. Assessment of the abuse liability of buspirone in recreational sedative users. J. Clin. Psychiatry. 1982 ; 43 (suppl. 2): 69-74.

· Cole, J.O. & Yonkers, K.A. Nonbenzodiazepine anxiolytics. In Schatzberg, A. & Nemeroff, C.B. (eds.) Textbook of psychopharmacology. American Psychiatric Press. Washington, 1995.

Principio de página

D-E-F

· DeVane, C.L., Ware, M.R. & Lydiard, R.B. Pharmacokinetics, pharmacodynamics, and treatment issues of benzodizepines: alprazolam, adinazolam, and clonazepam. Psychopharmacol. Bull. 1991; 27:463-473.

· D'Mello, D.A., McNeil, J.A. & Harris, W. Buspirone supression of neuroleptic-induced akathisia : multiple case reports (letter). J. Clin. Psychopharmacol. 1989 ; 9 : 151-152.

· Eison, A.S. & Temple, D.L. Jr. Buspirone: review of its pharmacology and current perspectives on its mechanism of action. Am. J. Med. 1986 ; 80 (suppl. 3) :1-9.

· Eison, A.S. Azapirones: history of development. J. Clin. Psychopharmacol. 1990; 10 (suppl. 3):2S-5S.

· Fabre, L.F. Buspirone in the management of major depression : a placebo-controlled comparison. J. Clin. Psychiatry. 1990 ; 51 (suppl. 9) : 55-61.

· Feighner, J.P., Merideth, C.H. & Hendrickson, G.A. A double-blind comparison of buspirone and diazepam in outpatients with generalized anxiety disorder. J. Clin. Psychiatry. 1982 ; 43 (suppl. 2) : 69-74.

· Feighner, J.P. Buspirone in the long-term treatment of generalized anxiety disorder. J. Clin. Psychiatry. 1987; 48 (suppl. 12):3-6.

· File, S.E. The benzodiazepine receptor and its role in anxiety. Br. J. Psychiatry. 1988; 152:599-600.

· Finkle, B.S., McCloskey, K.L. & Goodman, L.S. Diazepam and drug associated deaths. JAMA. 1979; 242:428.

· Fleming, J.A., Bourgouin, J. & Hamilton, P. A sleep laboratory evaluation of the long-term efficacy of zopiclone. Can. J. Psychiatry. 1988 ; 33 : 103-107.

· Frattola, L., Garreau, M., Pioti, R. et al. Comparison of the efficacy, safety and withdrawal of alpidem and alprazolam in anxious patients. Br. J. Psychiatry. 1994 ; 165 : 94-100.

Principio de página

G

· Gallager, D., Lokoski, J., Consalves, S. & Rauch, S. Chronic benzodiazepine treatment decreases postsynaptic GABA sensitivity. Nature. 1984 ; 308 : 74-77.

· Gawin, F., Compton, M. & Byck, R. Buspirone reduces smoking (letter). Arch. Gen. Psychiatry. 1989 ; 46 : 288-289.

· Gelenberg, A.J. Academic highlights-buspirone: seven year update. J. Clin. Psychiatry. 1994; 55:222-229.

· Godbout, R. et al. 5-HT1A agonists in anxiety disorders (Tandospirone). Neuropharmacology. 1991; 30.

· Goldberg, H.L. & Finnerty, R.J. The comparative efficacy of buspirone and diazepam in the treatment of anxiety. Am. J. Psychiatry. 1979; 136:1184-1187.

· Goldberg, H.L. & Finnerty, R.J. Comparison of buspirone in two separate studies. J. Clin. Psychiatry. 1982 ; 43 (suppl. 2) : 87-91.

· Goff, D.C., Midha, K.K., Brotman, A.W. et al. An open trial of buspirone added to neuroleptics in schizophrenic patients. J. Clin. Psychopharmacol. 1991 ; 11 : 193-197.

· Grady, T.A., Pigott, T.A., L'Heureux, F. et al. Double-blind study of adjuvant buspirone for fluoxetine-treated patients with obsessive-compulsive disorder. Am. J. psychiatry. 1993 ; 150 : 819-821.

· Greenblatt, D.J. et al. Acute overdosage with benzodiazepine derivates. Clin. Pharmacol. Ther. 1977 ; 4 : 497-514.

· Greenblatt, D.J., Abernethy, D.R., Locniskar, A. et al. Age, sex, and nitrazepam kinetics : relation to antipyrine disposition. Clin. Pharmacol. Ther. 1985 ; 38 : 697-703.

· Greenblatt, D.J., Harmatz, J.S., Engelhardt, N. et al. Pharmacokinetic determinants of dynamic differences among three benzodiazepine hypnotics. Arch. Gen. Psychiatry. 1989 ; 46 : 326-332.

· Greenblatt, D.J. et al. Sensitivity to triazolam in the elderly. N. Engl. J. Med. 1991; 324:1691-1698.

· Greenblatt, D.J., Preskorn, S.H., Cotteau, M.M. et al. Fluoxetine impairs clearance of alprazolam but not of clonazepam. Clin. Pharmacol. Ther. 1992; 52:479-486.

· Greenblatt, D.J., Harmatz, J.S. & Shader, R.I. Plasma alprazolam concentrations: relation to efficacy and side effects in the treatment of panic disorder. Arch. Gen. Psychiatry. 1993; 50:715-722.

· Griffiths, R.R. & Wolf, B. Relative abuse liability of different benzodiazepines in drug abusers. J. Clin. Psychopharmacol. 1990 ; 10 : 237-243.

· Gualtieri, C.T. Buspirone for the behavior problems of patients with organic brain disorders (letter). J. Clin. Psychopharmacol. 1991 ; 11 : 280-281.

Principio de página

H-I-J

· Harvey, S.C. Hypnotics and sedatives. In Goodman & Gilman. The pharmacological basis of therapeutics. 2a edn. MacMillan. New York, 1985.

· Hoehn-Saric, R. et al. Differential effects of alprazolam and imipramine in generalized anxiety disorder: somatic versus psychic symptoms. J. Clin. Psych.: 1988; 49.

· Iruela, L.M., Ibañez-Rojo, V., Caballero, L. et al. Buspirone-induced mania : possible interaction with disulfiram. Br. J. Psychiatry. 1991 ; 159 : 136-137.

· Jacobsen, F.M. Possible augmentation of antidepressant response by buspirone. J. Clin. Psychiatry. 1991 ; 52 : 217-220.

· Jenike, M.A. & Baer, L. An open trial of buspirone in obsessive-compulsive disorder. Am. J. Psychiatry. 1988 ; 145 : 1285-1286.

· Joffe, R.T. & Schuller, D.R. An open study of buspirone augmentation of serotonin reuptake inhibitors in refractory depression. J. Clin. Psychiatry. 1993 ; 54 : 269-271.

Principio de página

K-L

· Kim, Y.D. et al. Comparison of effect of zopiclone and brotizolam on sleep EEG by quantitative evaluation in healthy young women. Sleep: 1993; 16/7.

· Kranzler, H.R. & Meyer, R.E. An open trial of buspirone in alcoholics (letter). J. Clin. Psychopharmacol. 1989; 9:379-380.

· Kranzler, H.R., Burleson, J.A., Del Boca, F.K. et al. Buspirone treatment of anxious alcoholics - A placebo controlled trial. Arch. Gen. Psychiatry. 1994 ; 51 : 720-731.

· Lesser, I.M. et al. Alprazolam plasma concentrations and treatment response in panic disorder and agoraphobia. Am. J. Psychiatry. 1992; 149:1556-1562.

· Liebowitz, M.R., Schneier, F.R., hollander, E. et al. Treatment of social phobia with drugs other than benzodiazepines. J. Clin. Psychiatry. 1991 ; 52 (suppl. 11) : 10-15.

Principio de página

M

· Markovitz, P.J., Stagno, S.J. & Calabrese, J.R. Buspirone augmentation of fluoxetine in obsessive compulsive disorder. Am. J. Psychiatry. 1990 ; 147 : 798-800.

· Mattila, M.J., Aranko, K. & Seppala, T. Acute effects of buspirone and alcohol on psychomotor skills. J. Clin. Psychiatry. 1982 ; 43 (suppl. 2) : 56-60.

· McCall, W.V., Shelp, F.E. & McDonald, W.M. Controlled investigation of the amobarbital interview for catatonic mutism. Am. J. Psychiatry. 1992 ; 149 : 202.

· McDougle, C.J., Goodman, W.K., Leckman, J.F. et al. Limited therapeutic effect of addition of buspirone in fluvoxamine-refractory obsessive-compulsive disorder. Am. J. Psychiatry. 1993 ; 150 : 647-649.

· Meller, E., Goldstein, M. & Bohmaker, K. Receptor reserve for 5-hydroxytryptamine-1A-mediated inhibition of serotonin synthesis : possible relationship to anxyolitic properties of 5-hydroxytryptamine-1A agonists. Mol. Pharmacol. 1990 ; 37 : 231-237.

· Meltzer, H.Y., Flemming, R. & Robertson, A. The effect of buspirone on prolactin and growth hormone secretion in man. Arch. Gen. Psychiatry. 1983; 40:1099-1102.

· Mendelson, W.B., Maczaj, M. & Holt, J. Buspirone administration to sleep apnea patients (letter). J. Clin. Psychopharmacol. 1991 ; 11 : 71-72.

· Moskowitz, H. & Smiley, A. Effects of chronically administered buspirone and diazepam on driving-related skills performance. J. Clin. Psychiatry. 1982 ; 43 (suppl. 2) : 45-55.

· Moss, L.E., Neppe, V.M. & Drevets, W.C. Buspirone in the treatment of tardive dyskinesia. J. Clin. Psychopharmacol. 1993 ; 13 : 204-209.

· Munjack, D.J. et al. Alprazolam, propranolol, and placebo in the treatment of panic disorder and agoraphobia with panic attacks. J. Clin. Psychoph.: 1989; 68.

Principio de página

N-O-P

· Newton, R.E., Casten, G.P., Alms, D.R. et al. The side effect profile of buspirone in comparison to active controls and placebo. J. Clin. Psychiatry. 1982 ; 43 (suppl. 2) : 100-102.

· Nishino, S. Mignot, E. & Dement, W.C. Sedative-hypnotics. In Schatzberg, A. & Nemeroff, C.B. (eds.) Textbook of psychopharmacology. American Psychiatric Press. Washington, 1995.

· Noyes, R. et al. Diazepam and propranolol in panic disorder and agoraphobia. Arch. Gen. Psychiatry. 1984; 41:287-292.

· Olkkola, K.T., Backman, J.T. & Neuvonen, P.J. Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole. Clin. Pharmacol. Ther. 1994 ; 55 : 481-485.

· Pecknold, J.C., Matas, M., Howarth, B.G. et al. Evaluation of Buspirone as an antianxiety agent : buspirone and diazepam vs. Placebo. Am. J. Psychiatry. 1989 ; 34 : 766-771.

· Perucca, E., Gatti, G., Cipolla, G. et al. Inhibition of diazepam metabolism by fluovoxamine : a pharmacokinetic study in normal volunteers. Clin. Pharmacol. Ther. 1994 ; 56 : 471-476.

· Pigott, T.A., L'Heureux, F., Hill, J.L. et al. A double-blind study of adjuvant buspirone hydrochloride in clomipramine-treated patients with obsessive-compulsive disorder. J. Clin. Psychopharmacol. 1992 ; 12 : 11-18.

Principio de página

R

· Rall, T.W. Hypnotics and sedatives. In Goodman & Gilman's The Pharmacological Basis of Therapeutics. Gilman, A.G., Rall, T.W., Nies, A.S. et al. (eds.). New York, McGraw-Hill, 1993.

· Rapoport, D.M., Greenberg, H.E. & Goldring, R.M. Differing effects of the anxiolytic agents buspirone and diazepam on control of breathing. Clin. Pharmacol. Ther. 1991 ; 49 : 394-401.

· Ray, W.A., Griffin, M.R., Schaffner, W.S., et al. Psychotropic drug use and the risk of hip fracture. N. Engl. J. Med. 1987 ; 316 : 363-369.

· Ratey, J., Sovner, R., Mikkelsen, E. et al. Buspirone therapy for maladaptative behavior and anxiety in developmentally disabled persons. J. Clin. Psychiatry. 1989 ; 50 : 382-384.

· Ratey, J., Sovner, R., Parks, A. et al. Buspirone treatment of aggression and anxiety in mentally retarded patients : a multiple baseline, placebo lead-in study. J. Clin. Psychiatry. 1991 ; 52 : 159-162.

· Ray, W.A., Griffin, M.R. & Downey, W. Benzodiazepines of long and short elimination half-life and the risk of hip fracture. JAMA. 1989 ; 262 : 3303-3307.

· Realmuto, G.M., August, G.J. & Garfinkel, B.D. Clinical effect on buspirone in autistic children. J. Clin. Psychopharmacol. 1989 ; 9 : 122-125.

· Riblet, L.A., Taylor, D.P., Eison, M.S. et al. Pharmacology and neurochemistry of buspirone. J. Clin. Psychiatry. 1982 ; 43 (suppl. 2) : 11-16.

· Rickels, K., Weissman, K., Norstad, N. et al. Buspirone and diazepam in anxiety : a controlled study. J. Clin. Psychiatry. 1982 ; 43 (suppl. 2) : 81-86.

· Rickels, K. et al. Long-term treatment of anxiety and risk of withdrawal: Prospective comparison of clorazepate and buspirone. Arch. Gen. Psychiatry. 1988; 45:444-450.

· Rickels, K. & Schweizer, E. The clinical course and long-term management of generalized anxiety disorder. J. Clin. Psychopharmacol. 1990 ; 10 : 101S-110S.

· Rickels, K., Schweizer, E., Case, W.G. et al. Long-term therapeutic use of benzodiazepines, I : effects of abrupt discontinuation. Arch. Gen. Psychiatry. 1990 ; 47 : 899-907.

· Rickels, K., Amsterdam, J., Clary, C. et al. Buspirone in major depression: a controlled study. J. Clin. Psychiatry. 1991 ; 52 : 34-38.

· Romach, M., Busto, U., Somer, G. et al. Clinical aspects of chronic use of alprazolam and lorazepam. Am. J. Psychiatry. 1995 ; 152 : 1161-1167.

· Rosser, W.W. Benzodiazepinas. Wyeth-Ayerst. 1988.

· Roy-Byrne, P. & Hommer, D. Benzodiazepine withdrawal. The American Journal of medicine: 1988; 84.

· Ruffalo, R.L. & Thompson, J.F. Effect of cimetidine on the clearance of benzodiazepines. N. Engl. J. Med. 1980; 303:753-754.

· Ruiz, P. Benzodiacepinas: una perspectiva social. XVII Congreso Latinoamericano de Psiquiatría. Caracas.1992.

· Rush, C.R. & Griffiths, R.R. Zolpidem, triazolam and temazepam : behavioral and subject-rated effects in normal volunteers. J. Clin. Psychopharamacol. 1996 ; 16 : 146-157.

Principio de página

S

· Schmider, J., Greenblatt, D.J., Von Moltke, L. & Shader, R.I. Relationship of in vitro data on drug metabolism to in vivo pharmacokinetics and drug interactions : implications for diazepam disposition in humans (editorial). J. Clin. Psychopharmacol. 1996 ; 16 : 267-.272.

· Schneier, F.R. et al. Buspirone in social phobia. J. Clin. Psychopharmacol. 1993; 13:251-256.

· Schweizer, E., Rickels, K. & Lucki, J. Resistance to the anti-anxiety effect of buspirone in patients with a history of benzodiazepine use. N. Engl. J. Med. 1982; 314 : 719-720.

· Schweizer, E. et al. Lorazepam vs alprazolam in the treatment of panic disorder. Psychopharmacol. Bull. 1988; 24:224-227.

· Sellers, E.M., Schneiderman, J.F., Romach, M.K. et al. Comparative drug effects and abuse liability of lorazepam, buspirone and secobarbital in nondependent subjects. J. Clin. Psychopharmacol. 1992 ; 12 : 79-85.

· Shader, R.I. & Greenblatt, D.J. Use of benzodiazepines in anxiety disorders. N. Engl. J. Med. 1993; 328:1398-1405.

· Shlarf, M.B. et al. Efficacy of Zolpidem in the treatment of chronic insomnia. XIX CINP Congress. Washington DC. 1994.

· Skegg, D.C.G., Richards, S.M. & Doll, R. Minor tranquilizers and road accidents. BMJ. 1979 ; 1 : 917-919.

· Skolnick, P. & Paul, S.M. Buspirone : chemistry, pharmacology and behavior. J. Clin. Psychiatry. 1982 ; 43 : (suppl. 2) : 40-42.

· Smiley, A. Effects of minor tranquilizers and antidepressants on psychomotor performance. J. Clin. Psychiatry. 1987 ; 48 (suppl. 12) : 22-28.

· Springhouse Corporation. Physician's 1993. Drug handbook. Pennsylvania

· Stern, T.A., Caplan, R.A. & Cassem, N.H. Use of benzodiazepines in a coronary care unit. Psychosomatics. 1987 ; 28 : 19-23.

Principio de página

T-U

· Tallman, J.F., Thomas, J.W. & Gallager, D.W. GABAergic modulation of benzodiazepine binding site sensitivity. Nature. 1978; 274:383-385.

· Tanquary, J. & Masand, P. Paradoxical reaction to buspirone augmentation of fluoxetine (letter). J. Clin. Psychopharmacol. 1990 ; 10 : 377.

· Taylor, D.P. Serotonin agents in anxiety. Ann. N.Y. Acad Sci. 1989 ; 600 : 545-557.

· Tiller, J.W.G., Dakis, J.A. & Shaw, J.M. Short-term buspirone treatment in disinhibition with dementia. Lancet. 1988 ; 2 : 510.

· Tollefson, G.D., Lancaster, S.P. & Montagne-Clouse, J. The association of buspirone and its metabolic 1-pyrimidinylpiperazine in the remission of comorbid anxiety with depressive features and alcohol dependency. Psychopharmacol. Bull. 1991; 27:163-170.

· Udelman, H.D. & Udelman, D.L. Concurrent use of buspirone in anxious patients during withdrawal from alprazolam therapy. J. Clin. Psychiatry. 1990; 51 (suppl. 9):46-50.

· USP-DI, Drug Information for the Health Care Professional. 17th edition. Rockville, MD, United States Pharmacopeial Convention, Inc., 1997.

Principio de página

V-W-Y-Z

· Varhe, A., Olkkola, K.T. & Neuvonen, P.J. Oral triazolam is potentially hazardous to patients receiving systemic antimycotics ketoconazole or itraconazole. Clin. Pharmacol. Ther. 1994 ; 56 : 601-607.

· Wheatley, D. Zopiclone : a non-benzodiazepine hypnptic contrlled comparison to temazepam in insomnia. Br. J. Psychiatry. 1985 ; 146 : 312-314.

· Yudofsky, S.C., Silver, J.M. & hales, R.E. Pharmacologic management of agression in the elderly. J. Clin. Psychiatry. 1990 ; 51 (suppl. 10) : 22-28.

· Zorumski, C.F. & Isenberg, K.E. Insights into the structure and function of GABA-benzodiazepines receptors ion channels and psychiatry. Am. J. Psychiatry. 1991; 148:162-173.

Principio de página

Comentarios             Principio de página